Equivalent long-term effects on the kidney are attributed to angiotensin-converting enzyme inhibitors (ACEI) and @entity196 ( @entity11882 ). Nevertheless, it is unknown to which degree effects of these compounds on individual inflammatory mediators, including matrix metalloproteinases (MMP), are comparable. On the basis of structural and functional differences, it was hypothesized that ACEI and @entity11882 differentially regulate MMP activity. In a randomized, prospective crossover trial, the effect of an ACEI ( @entity10959 ; 20 mg/d) and of an @entity11882 ( @entity7056 ; 150 mg/d) on MMP activity was evaluated. Ten @entity101 @entity1 with @entity631 and normal or mildly reduced @entity1011 clearance were studied. MMP activity and @entity2843 ( @entity2843 ) levels were analyzed in serum and urine: without therapy, with ACEI, with @entity11882 , and with both agents combined. Treatment periods continued for 6 wk separated by periods of 4 wk each without therapy. Untreated @entity1 with @entity631 displayed distinctively higher serum levels of @entity1476 but much lower @entity3334 concentrations compared with healthy control subjects. Immunohistology of @entity1476 and @entity1495 in kidney biopsy specimen was accordingly. However, these @entity1 excreted higher amounts of @entity1476 and @entity1495 in urine than healthy control subjects, possibly reflecting @entity8 . In @entity1 with @entity631 , ACEI significantly reduced overall MMP serum activity to 25%, whereas @entity11882 did not show any effect. Activities of @entity3334 were also significantly inhibited by @entity10959 but not by @entity7056 . Levels of @entity2843 /-2 remained unaffected. In conclusion, ACEI and @entity11882 differentially regulate MMP activity, which may ultimately have consequences in certain types of MMP-dependent @entity631 .

Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in XXXX with @entity631 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['ongoing glomerular inflammation'] @entity3334 :: ('4312', 'Gene') :: ['MMP-1/-2/-8/-9', 'MMP-1/-8/-9'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive'] @entity1476 :: ('4313', 'Gene') :: ['MMP-2'] @entity10959 :: ('MESH:D017328', 'Chemical') :: ['fosinopril'] @entity7056 :: ('MESH:C081309', 'Chemical') :: ['irbesartan'] @entity196 :: ('MESH:D020754', 'Disease') :: ['angiotensin II type 1 receptor blockers'] @entity2843 :: ('7076', 'Gene') :: ['TIMP', 'tissue inhibitors of metalloproteinase', 'TIMP-1'] @entity1495 :: ('4318', 'Gene') :: ['MMP-9'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity11882 :: ('OMIM:611809', 'Disease') :: ['ARB'] @entity631 :: ('MESH:D005921', 'Disease') :: ['glomerulonephritis']
@entity1 :: (9606,Species) :: ['patients']
